Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists.

Diabetes Mellitus, Type 2 Female Glucagon-Like Peptide 1 Glucagon-Like Peptide-1 Receptor / agonists Glucose Humans Hypoglycemic Agents / therapeutic use Kidney Male Retrospective Studies Sodium Sodium-Glucose Transporter 2 Inhibitors / pharmacology Symporters
Glucagon-like peptide 1 receptor agonist Renal outcome Sodium-glucose cotransporter 2 inhibitors

Journal

Diabetes research and clinical practice
ISSN: 1872-8227
Titre abrégé: Diabetes Res Clin Pract
Pays: Ireland
ID NLM: 8508335

Informations de publication

Date de publication:
Mar 2022
Historique:
received: 04 11 2021
revised: 24 12 2021
accepted: 31 01 2022
pubmed: 9 2 2022
medline: 20 4 2022
entrez: 8 2 2022
Statut: ppublish

Résumé

This study aimed to clarify the differences in how sodium glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP1Ra) influence kidney function in Japanese patients with type 2 diabetes mellitus (T2DM). We retrospectively built two databases of patients with T2DM who visited the clinics of members of Kanagawa Physicians Association. We defined the renal composite outcome as either progression of albuminuria status and/or > 15% deterioration in estimated glomerular filtration rate (eGFR) per year. We used propensity score matching to compare patient outcomes after SGLT2i and GLP1Ra treatments. The incidence of renal composite outcomes was significantly lower in SGLT2i-treated patients than in GLP1Ra-treated patients (n = 15[11%] and n = 27[20%], respectively, P = 0.001). Annual eGFR changes (mL/min/1.73 m Renal composite outcome incidence was lower in SGLT2i-treated patients than in GLP1Ra-treated patients.

Identifiants

DOI: 10.1016/j.diabres.2022.109231 PMID: 35131376
pubmed: 35131376
pii: S0168-8227(22)00043-2
doi: 10.1016/j.diabres.2022.109231
pii:
doi:

Substances chimiques

Glucagon-Like Peptide-1 Receptor 0
Hypoglycemic Agents 0
Sodium-Glucose Transporter 2 Inhibitors 0
Symporters 0
Glucagon-Like Peptide 1 89750-14-1
Sodium 9NEZ333N27
Glucose IY9XDZ35W2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

109231

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

Kazuo Kobayashi (K)

Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan; Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan. Electronic address: k-taishi@xc4.so-net.ne.jp.

Masao Toyoda (M)

Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, lsehara, Japan.

Nobuo Hatori (N)

Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.

Hiroyuki Sakai (H)

Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.

Takayuki Furuki (T)

Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.

Keiichi Chin (K)

Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.

Moritsugu Kimura (M)

Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, lsehara, Japan.

Nobumichi Saito (N)

Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, lsehara, Japan.

Tomohiko Kanaoka (T)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Togo Aoyama (T)

Division of Nephrology, Department of internal medicine, Kitasato University School of Medicine, Sagamihara, Japan.

Tomoya Umezono (T)

Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.

Shun Ito (S)

Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.

Daisuke Suzuki (D)

Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.

Hiroshi Takeda (H)

Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.

Fuyuki Minagawa (F)

Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.

Hisakazu Degawa (H)

Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.

Hideo Machimura (H)

Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.

Toshimasa Hishiki (T)

Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.

Shinichi Umezawa (S)

Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.

Hidetoshi Shimura (H)

Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.

Shinichi Nakajima (S)

Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.

Hareaki Yamamoto (H)

Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.

Kazuyoshi Sato (K)

Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.

Masaaki Miyakawa (M)

Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.

Yasuo Terauchi (Y)

Department of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Kouichi Tamura (K)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Akira Kanamori (A)

Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies endocriniennes › Diabète › Diabète de type 2 › Comparison of renal outcomes between sodium...
questionsmedicales.fr › Hormones gastrointestinales › Peptides glucagon-like › Glucagon-like peptide 1 › Comparison of renal outcomes between sodium...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur hormone gastrointestinale › Récepteurs des peptides similaires au glucagon › Récepteur du peptide-1 similaire au glucagon › Comparison of renal outcomes between sodium...
questionsmedicales.fr › Glucides › Sucres › Oses › Hexose › Glucose › Comparison of renal outcomes between sodium...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Comparison of renal outcomes between sodium...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hypoglycémiants › Comparison of renal outcomes between sodium...
questionsmedicales.fr › Appareil urogénital › Voies urinaires › Rein › Comparison of renal outcomes between sodium...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Comparison of renal outcomes between sodium...
questionsmedicales.fr › Produits chimiques inorganiques › Métaux › Métaux légers › Sodium › Comparison of renal outcomes between sodium...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hypoglycémiants › Inhibiteurs du cotransporteur sodium-glucose de type 2 › Comparison of renal outcomes between sodium...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Protéines de transport membranaire › Pompes ioniques › Symporteurs › Comparison of renal outcomes between sodium...